Please assess the completion status of the following clinical trial:

Trial Title: Global Study to Assess the Safety and Effectiveness of Edoxaban (DU-176b) vs Standard Practice of Dosing With Warfarin in Patients With Atrial Fibrillation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* 21 years of age or older; male or female.~* Able to provide written informed consent.~* History of documented AF within the prior 12 months~* A moderate to high risk of stroke, as defined by CHADS2 index score of at least 2~Exclusion Criteria:~* Transient atrial fibrillation secondary to other reversible disorders~* Subjects with moderate or severe mitral stenosis, unresected atrial myxoma, or a mechanical heart valve~* Subjects with any contraindication for anticoagulant agents;~* Subjects with conditions associated with high risk of bleeding or have known or suspected hereditary or acquired bleeding disorders~* Females of childbearing potential including the following:~  * Females with a history of tubal-ligation~ * Females less than 2 years post-menopausal

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Warfarin/placebo edoxaban (Type: ACTIVE_COMPARATOR): Warfarin tablets plus placebo Edoxaban tablets
- high dose edoxaban/placebo warfarin (Type: EXPERIMENTAL): Edoxaban tablets (60mg) plus warfarin placebo tablets
- low dose edoxaban/placebo warfarin (Type: EXPERIMENTAL): Edoxaban tablets (30mg) plus warfarin placebo tablets

Based on this trial design, predict the completion outcome and termination type (if applicable).